Glenmark's specialty brand Ryaltris, was making much headway, he said, and the company had initiated "Proof-of-Concept" on four clinical oncology assets, that are part of the Glenmark/Ichnos pipeline, he added. Ichnos is Glenmark's US-based research oriented subsidiary.